SCHEDULE: FMR LLC Amends Regeneron Stake to 3.2%

FMR LLC and Abigail P. Johnson have filed an Amendment No. 7 to their Schedule 13G, reporting a 3.2% beneficial ownership stake in Regeneron Pharmaceuticals Inc. as of June 30, 2025.

Summary

• FMR LLC and Abigail P. Johnson filed an Amendment No. 7 to Schedule 13G regarding their beneficial ownership in Regeneron Pharmaceuticals Inc.
• They collectively beneficially own 3,359,562.56 shares of Regeneron Pharmaceuticals Inc. common stock.
• This ownership represents 3.2% of the total outstanding common stock of Regeneron Pharmaceuticals Inc.
• FMR LLC holds sole voting power over 3,156,857.64 shares.
• Both FMR LLC and Abigail P. Johnson hold sole dispositive power over 3,359,562.56 shares.
• The securities were acquired and are held in the ordinary course of business and not for the purpose of or with the effect of changing or influencing the control of the issuer.

Sentiment

Score: 5

Explanation: Neutral, as this is a routine regulatory disclosure of passive ownership and does not contain performance or strategic updates for the issuer.

Future Outlook

NA

Industry Context

NA

Stakeholder Impact

• Minimal impact on shareholders as it's a routine disclosure of a passive investment stake below the 5% threshold for active influence.

Key Dates

Keywords

Regeneron Pharmaceuticals, FMR LLC, Abigail P. Johnson, Schedule 13G, Beneficial Ownership, Common Stock, Pharmaceuticals, Biotechnology, Investment Management